{"id":"treatment-choice-tc","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TC works by blocking the interaction between CD47 and SIRPα on the surface of tumor cells, which can help the immune system recognize and attack cancer cells.","oneSentence":"Treatment Choice (TC) is a small molecule that targets the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:00.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT07432178","phase":"PHASE3","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-23","conditions":"Breast Cancer","enrollment":2288},{"nctId":"NCT05924672","phase":"PHASE2","title":"Efficacy of Ra-223 in PSMA PET Optimally Selected Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-08-30","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IVB Prostate Cancer AJCC v8","enrollment":2},{"nctId":"NCT05014828","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-09-18","conditions":"Advanced Solid Tumor","enrollment":58},{"nctId":"NCT02693665","phase":"NA","title":"Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer","status":"COMPLETED","sponsor":"Maureen Lyon","startDate":"2016-07-16","conditions":"Cancer","enrollment":260},{"nctId":"NCT06752135","phase":"","title":"Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience","status":"TERMINATED","sponsor":"Azienda Policlinico Umberto I","startDate":"2024-04-10","conditions":"Cervical Carcinoma","enrollment":97},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT01696032","phase":"PHASE2","title":"SGI-110 in Combination With Carboplatin in Ovarian Cancer","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT02348489","phase":"PHASE3","title":"SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2015-03-19","conditions":"Leukemia, Myeloid, Acute","enrollment":815},{"nctId":"NCT00911508","phase":"NA","title":"Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-11-13","conditions":"Atrial Fibrillation, Arrhythmia","enrollment":2204},{"nctId":"NCT04280185","phase":"NA","title":"HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-06-01","conditions":"Ovarian Cancer, Hyperthermic Intraperitoneal Chemotherapy","enrollment":202},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT02349685","phase":"NA","title":"The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Helicobacter Infection","enrollment":219},{"nctId":"NCT02808130","phase":"","title":"PERIODONTAL DISEASE AND HYPERLIPIDEMIA","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2013-01","conditions":"Hyperlipidemia, Periodontitis, Gingivitis","enrollment":90},{"nctId":"NCT02464774","phase":"NA","title":"Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer","status":"UNKNOWN","sponsor":"Xiaoming Xie","startDate":"2015-07","conditions":"Breast Cancer","enrollment":464},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00578617","phase":"NA","title":"Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-09","conditions":"Atrial Fibrillation, Arrhythmia","enrollment":60},{"nctId":"NCT00249561","phase":"PHASE1, PHASE2","title":"Colorado Women's TC Project","status":"COMPLETED","sponsor":"National Development and Research Institutes, Inc.","startDate":"2001-09","conditions":"Substance-Related Disorders","enrollment":610}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":584,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Treatment Choice (TC)","genericName":"Treatment Choice (TC)","companyName":"Astex Pharmaceuticals, Inc.","companyId":"astex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Treatment Choice (TC) is a chemotherapy regimen consisting of Docetaxel and Cyclophosphamide, administered for 4 cycles followed by endocrine therapy. It is a small molecule modality, used to treat various conditions including Breast Cancer, Advanced Solid Tumor, Atrial Fibrillation, Arrhythmia, and Helicobacter Infection.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}